ResMed Inc. (RMD)

NYSE: RMD · IEX Real-Time Price · USD
212.24
-2.86 (-1.33%)
Sep 27, 2022 3:59 PM EDT - Market closed
-1.33%
Market Cap 31.08B
Revenue (ttm) 3.58B
Net Income (ttm) 779.44M
Shares Out 146.42M
EPS (ttm) 5.30
PE Ratio 40.05
Forward PE 33.00
Dividend $1.70 (0.80%)
Ex-Dividend Date Aug 17, 2022
Volume 233,528
Open 217.15
Previous Close 215.10
Day's Range 211.51 - 217.60
52-Week Range 189.40 - 275.66
Beta 0.50
Analysts Buy
Price Target 258.40 (+21.7%)
Earnings Date Oct 26, 2022

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software in... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 2, 1995
CEO Michael Farrell
Employees 8,160
Stock Exchange NYSE
Ticker Symbol RMD
Full Company Profile

Financial Performance

In 2022, ResMed's revenue was $3.58 billion, an increase of 11.93% compared to the previous year's $3.20 billion. Earnings were $779.44 million, an increase of 64.26%.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is 258.4, which is an increase of 21.75% from the latest price.

Price Target
$258.4
(21.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

1 day ago - Zacks Investment Research

ResMed Announces Participation in the Bank of America Global Healthcare Conference

SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bank of America Global Health...

2 weeks ago - GlobeNewsWire

ResMed Announces Participation in the 20th Annual Morgan Stanley Global Healthcare Conference

SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the 20th Annual Morg...

3 weeks ago - GlobeNewsWire

Over 480 Million People Estimated to Have COPD, World's Third Deadliest Disease, ResMed Study Reports

BARCELONA, Spain, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by Res...

3 weeks ago - GlobeNewsWire

Reasons Why You Should Retain ResMed (RMD) Stock For Now

Investors are optimistic about ResMed's (RMD) better-than-expected results and robust device sales.

4 weeks ago - Zacks Investment Research

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

1 month ago - Zacks Investment Research

ResMed (RMD) Q4 Earnings Beat Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0.68% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

ResMed Q4 Preview: Rebound Quarter Inbound?

RMD has primarily exceeded the Zacks Consensus EPS Estimate. However, the company registered an 8% bottom-line miss in its latest quarter.

1 month ago - Zacks Investment Research

ResMed Acquires Leipzig-based mementor with Insomnia Digital Health Solution somnio

MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) --  ResMed (NYSE: RMD, ASX: RMD) today announced the acquisition of Leipzig-based company mementor; the deal was completed Monda...

1 month ago - GlobeNewsWire

ResMed to Report Fourth Quarter Fiscal 2022 Earnings on August 11, 2022

SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2022 on Thursday, Au...

2 months ago - GlobeNewsWire

Reasons Why You Should Invest in ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.

2 months ago - Zacks Investment Research

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

NUVA vs. RMD: Which Stock Is the Better Value Option?

Other symbols: NUVA
2 months ago - Zacks Investment Research

7 Growth Stocks to Buy in July 2022

The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks. The post 7 Growth Stocks to Buy in July 2022 appeared first on Inves...

Other symbols: ADIFASTLRCXNETSHOPTER
2 months ago - InvestorPlace

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating ResMed Inc.

Wilmington, Delaware--(Newsfile Corp. - June 29, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of ResMed Inc. (NYSE: RMD) on behalf of stockholders.To ...

2 months ago - Newsfile Corp

ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany

ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.

3 months ago - Zacks Investment Research

ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

SAN DIEGO and HILDESHEIM, Germany, June 14, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German leader in out-of-...

3 months ago - GlobeNewsWire

ResMed Announces Participation in the 43rd Annual Goldman Sachs Global Healthcare Conference

SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Goldman Sachs Global Healthcar...

3 months ago - GlobeNewsWire

ResMed Announces Participation in the 42nd Annual William Blair Growth Stock Conference

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the William Blair Growth Stock Conference on...

3 months ago - GlobeNewsWire

ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference

SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions C...

4 months ago - GlobeNewsWire

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led...

4 months ago - GlobeNewsWire

ResMed Announces Leadership Change

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new posi...

4 months ago - GlobeNewsWire

ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline

Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.

4 months ago - Zacks Investment Research

ResMed (RMD) Q3 Earnings and Revenues Lag Estimates

ResMed (RMD) delivered earnings and revenue surprises of -8.33% and 4.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

4 months ago - GlobeNewsWire

ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tues...

4 months ago - GlobeNewsWire